Paul Joseph DysonPaul Dyson joined the Institute of Chemical Sciences and Engineering at the EPFL in 2002 where he heads the Laboratory of Organometallic and Medicinal Chemistry and between 2008 and 2016 chaired the Institute. He has won several prizes including the Werner Prize of the Swiss Chemical Society in 2004, the Award for Outstanding Achievements in Bioorganometallic Chemistry in 2010, the Centennial Luigi Sacconi Medal of the Italian Chemical Society in 2011, the Bioinorganic Chemistry Award of the Royal Society of Chemistry in 2015, the European Sustainable Chemistry Award of the European Chemical Society in 2018 and the Green Chemistry Award from the Royal Society of Chemistry in 2020. He is also a Clarivate Highly Cited Researcher and has an H-index >110 (web of science and google scholar). He was elected a Fellow of the Royal Society of Chemistry in 2010, a Fellow of the European Academy of Science in 2019 and a life-long fellow of the American Association for the Advancement of Science in 2020. Over the years he has held visiting professorships at the University of Bourgogne, University of Pierre et Marie Curie, University of Vienna, University of Rome Tor Vergara, Chimie Paristech and Shangai Jiao Tong University.Since 2016 he has been Member of the Council of the Division of Mathematics, Natural and Engineering Sciences at the Swiss National Science Foundation.Between 2016-2021 he has been Member of the Council of the Division of Mathematics, Natural and Engineering Sciences at the Swiss National Science Foundation. In 2021 he was appointed Dean of the Faculty of Basic Sciences.
Li TangEducation and Training Postdoctoral Fellow, Massachusetts Institute of Technology, 2013 - 2016 Ph.D., University of Illinois at Urbana-Champaign, 2007 - 2012 B.S., Peking University, 2003-2007
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Sandro CarraraSandro Carrara is an IEEE Fellow for his outstanding record of accomplishments in the field of design of nanoscale biological CMOS sensors. He is also the recipient of the IEEE Sensors Council Technical Achievement Award in 2016 for his leadership in the emerging area of co-design in Bio/Nano/CMOS interfaces. He is a Professor of the EPFL in Lausanne (Switzerland), and head of the "Bio/CMOS Interfaces" (BCI) research group. He is former professor of optical and electrical biosensors at the Department of Electrical Engineering and Biophysics (DIBE) of the University of Genoa (Italy) and former professor of nanobiotechnology at the University of Bologna (Italy). He holds a PhD in Biochemistry & Biophysics from University of Padua (Italy), a Master degree in Physics from University of Genoa (Italy), and a diploma in Electronics from National Institute of Technology in Albenga (Italy). His scientific interests are on electrical phenomena of nano-bio-structured films, and include CMOS design of biochips based on proteins and DNA. Along his carrier, he published 7 books, one as author with Springer on Bio/CMOS interfaces and, more recently, a Handbook of Bioelectronics with Cambridge University Press. He has more than 250 scientific publications and is author of 13 patents. He is now Editor-in-Chief of the IEEE Sensors Journal, the largest journal among 2019 IEEE publications; he is also founder and Editor-in-Chief of the journal BioNanoScience by Springer, and Associate Editor of IEEE Transactions on Biomedical Circuits and Systems. He is a member of the IEEE Sensors Council and his Executive Committee. He was a member of the Board of Governors (BoG) of the IEEE Circuits And Systems Society (CASS). He has been appointed as IEEE Sensors Council Distinguished Lecturer for the years 2017-2019, and CASS Distinguished Lecturer for the years 2013-2014. His work received several international recognitions: several Top-25 Hottest-Articles (2004, 2005, 2008, 2009, and two times in 2012) published in highly ranked international journals such as Biosensors and Bioelectronics, Sensors and Actuators B, IEEE Sensors journal, and Thin Solid Films; a NATO Advanced Research Award in 1996 for the original contribution to the physics of single-electron conductivity in nano-particles; six Best Paper Awards at the IEEE Sensors Conference 2019 (Montreal) in 2019, Conferences IEEE NGCAS in 2017 (Genoa), MOBIHEALTH in 2016 (Milan), IEEE PRIME in 2015 (Glasgow), in 2010 (Berlin), and in 2009 (Cork); three Best Poster Awards at the EMBEC Conference in 2017 (Tampere, Finland), Nanotera workshop in 2011 (Bern), and NanoEurope Symposium in 2009 (Rapperswil). He also received the Best Referees Award from the journal Biosensor and Bioelectronics in 2006. From 1997 to 2000, he was a member of an international committee at the ELETTRA Synchrotron in Trieste. From 2000 to 2003, he was scientific leader of a National Research Program (PNR) in the filed of Nanobiotechnology. He was an internationally esteemed expert of the evaluation panel of the Academy of Finland in a research program for the years 2010-2013. He has been the General Chairman of the Conference IEEE BioCAS 2014, the premier worldwide international conference in the area of circuits and systems for biomedical applications
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
